A clinical-stage oncology firm advancing innovative antibody-drug conjugates targeting hard-to-treat solid tumors with a balance sheet featuring $224.5M in cash and equivalents as of the latest reporting period.
Investors might consider KURA for its proprietary ADC technology platform which offers a potential breakthrough in treating resistant solid tumors, a large addressable market with high unmet need. The company's substantial cash position of $224.5M provides a long runway to advance its pipeline through critical clinical milestones without immediate equity dilution.
The stock carries extreme risk due to the lack of approved products and significant accumulated losses of nearly $900M, meaning the company has not yet proven commercial viability. Investors should avoid exposure if they are concerned about the high probability of clinical trial failures which could render the current asset base worthless.
Kura Oncology, Inc. (NASDAQ: KURA) is a clinical-stage biotechnology company developing next-generation small molecule therapies for solid tumors and other difficult-to-treat cancers. The company primarily operates in the United States and internationally, focusing on its proprietary antibody-drug conjugate platforms designed to overcome resistance mechanisms common in traditional cancer treatments.
Despite reporting a substantial net loss of $-174.0M and operating profit of $-193.2M, the company generated positive cash flow from operations of $134.3M, indicating effective cost management relative to its scale. The balance sheet remains robust with total assets of $760.2M and healthy working capital changes of $303.0M, though the significant retained earnings deficit suggests a history of heavy investment in research and development.
The global oncology market is rapidly evolving with a shift toward precision medicine and novel delivery systems like antibody-drug conjugates to improve patient outcomes in solid tumors. This sector is characterized by long development cycles, high regulatory hurdles, and significant capital requirements before reaching commercialization milestones.
| Metric | 2024 |
|---|---|
| Revenue | $53.9M |
| Cost of Revenue | $0 |
| Gross Profit | $53.9M |
| Operating Expenses | $247.1M |
| Operating Income | $-193.2M |
| R&D | $170.0M |
| G&A | $77.1M |
| Stock-Based Comp | $33.9M |
| Depreciation | $848.0K |
| Other OpEx | $0 |
| Non-Operating Income | $21.2M |
| Pre-Tax Income | $-172.0M |
| Income Tax | $2.0M |
| Continuing Ops | $-174.0M |
| Discontinued Ops | $0 |
| Net Income | $-174.0M |
| Minority Interest | $0 |
| Net to Common | $-174.0M |
| Metric | 2024 |
|---|---|
| Current Assets | $744.8M |
| Cash & Equivalents | $224.5M |
| Prepaid Expenses | $17.4M |
| Other Current Assets | $502.9M |
| Long-Term Assets | $15.3M |
| PP&E (Net) | $1.7M |
| Operating Leases | $5.8M |
| Other LT Assets | $7.8M |
| Total Assets | $760.2M |
| Current Liabilities | $78.7M |
| Accounts Payable | $1.5M |
| Current Debt | $2.6M |
| Current Leases | $1.9M |
| Deferred Revenue | $24.3M |
| Other Current Liab | $48.5M |
| Long-Term Liabilities | $267.8M |
| Long-Term Debt | $6.9M |
| LT Operating Leases | $5.2M |
| Other LT Liab | $1.8M |
| Total Liabilities | $346.5M |
| Shareholders' Equity | $413.6M |
| Retained Earnings | $-895.4M |
| AOCI | $764.0K |
| Total L&E | $760.2M |
| Metric | 2024 |
|---|---|
| Net Income (CFO) | $-174.0M |
| Non-Cash Adjustments | $5.3M |
| Working Capital Changes | $303.0M |
| Cash from Operations | $134.3M |
| Capital Expenditures | $472.0K |
| Cash from Investing | $-101.6M |
| Cash from Financing | $154.4M |
| FX Effect | $0 |
| Net Change in Cash | $187.1M |
| Beginning Cash | $37.3M |
| Ending Cash | $224.5M |
The company's revenue is currently derived from collaboration agreements, licensing fees, and milestone payments rather than direct product sales, as it remains in clinical development stages. Key therapeutic areas include solid tumor indications where KURA leverages its proprietary ADC technology to address unmet medical needs.
As a clinical-stage biotechnology company, Kura faces substantial risk of failure in ongoing or future clinical trials which could result in total loss of invested capital. The company carries a significant accumulated deficit of $-895.4M and negative net income of $-174.0M, creating pressure to secure additional financing before commercialization. Regulatory approval uncertainties for novel cancer therapies and potential delays in manufacturing scale-up present further operational challenges.
Kura Oncology possesses a unique competitive moat through its proprietary antibody-drug conjugate (ADC) platform capable of overcoming drug resistance mechanisms. The company benefits from strong cash reserves of $224.5M providing significant runway for R&D without immediate dilution pressure, and maintains a robust pipeline focused on high-value solid tumor indications.
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.